Sarilumab
Kevzara (sarilumab) is an antibody pharmaceutical. Sarilumab was first approved as Kevzara on 2017-05-22. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.
| Trade Name | Kevzara |
|---|---|
| Common Name | Sarilumab |
| Indication | rheumatoid arthritis |
| Drug Class | Monoclonal antibodies: fully human, immunomodulating |
